![Tomas Hode](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Lu Alleruzzo | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | 15 ans |
Bobby Sandage | M | 70 |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | 9 ans |
David Smoller | M | 60 |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
P. Kirk Warden | M | - |
Missouri Biotechnology Association
| - |
J. Kenneth Charles Knowles | M | 77 |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | 4 ans |
Derek Rapp | M | - |
Missouri Biotechnology Association
| - |
Saeid Esmaeilzadeh | M | 50 |
University of Stockholm
| 22 ans |
Charlie Bolten | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Siu Kit Lam | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Joseph Raker | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Theresa Visarius | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Robert Nordquist | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
Chen Wei | M | - |
Immunophotonics, Inc.
![]() Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | - |
John Sagartz | M | 58 |
Missouri Biotechnology Association
| - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Carl M. Svernlöv | M | - |
University of Stockholm
| 2 ans |
Sarah Al-Hajali | F | - |
University of Stockholm
| 1 ans |
Pawel Zbigniew Szydlowski | M | 43 |
University of Stockholm
| 1 ans |
Johan Carl Lundberg | M | 47 |
University of Stockholm
| 2 ans |
Shams Jorjani | M | 41 |
University of Stockholm
| 2 ans |
Pär Roosvall | M | 48 |
University of Stockholm
| 2 ans |
Thomas Kidane | M | - |
University of Stockholm
| 2 ans |
Kristoffer Eklund | M | 40 |
University of Stockholm
| 4 ans |
Jesper Funck | M | 45 |
University of Stockholm
| 4 ans |
Adam Lindberg | M | 46 |
University of Stockholm
| 1 ans |
Declan Fitzgerald Mac Guinness | M | 58 |
University of Stockholm
| 3 ans |
Jenny Cintra | F | 39 |
University of Stockholm
| 4 ans |
Eva Nahari | F | - |
University of Stockholm
| 1 ans |
Johanna Rutberg | F | 42 |
University of Stockholm
| 4 ans |
Erik Norström | M | - |
University of Stockholm
| 4 ans |
Sina Mostafavi | M | 42 |
University of Stockholm
| 3 ans |
Johan Pellbäck | M | - |
University of Stockholm
| 3 ans |
Carl Brusewitz | M | - |
University of Stockholm
| 3 ans |
Awais Manzur Sumra | M | - |
University of Stockholm
| 1 ans |
Silke Ernst | M | 57 |
University of Stockholm
| 3 ans |
Elena Viktorovna Tumanova | F | 66 |
University of Stockholm
| 4 ans |
Karl David Frykman | M | 52 |
University of Stockholm
| 6 ans |
Mattias Stenberg | M | 47 |
University of Stockholm
| 2 ans |
Martin Ragnar Andersson | M | 45 |
University of Stockholm
| 1 ans |
Helena Westerberg | M | - |
University of Stockholm
| 1 ans |
Sophia Evelina Bendz | F | 44 |
University of Stockholm
| 4 ans |
Per Ingvar Backlund | M | - |
University of Stockholm
| 3 ans |
Leif Vase Larsen | M | 61 |
University of Stockholm
| 2 ans |
Daniel Nyhrén Edeen | M | 43 |
University of Stockholm
| 1 ans |
Nanna Andersen | F | - |
University of Stockholm
| 4 ans |
Martin Lundvall | M | - |
University of Stockholm
| 2 ans |
Bertil Andersson | M | - |
University of Stockholm
| 7 ans |
Tobias Hägglöv | M | 46 |
University of Stockholm
| 1 ans |
Rickard Waldenlind | M | - |
University of Stockholm
| 4 ans |
Erika Karin Elisabeth Henriksson | F | 43 |
University of Stockholm
| 2 ans |
Marcus Jennekvist | M | 39 |
University of Stockholm
| 2 ans |
Joakim Buddgård | M | 44 |
University of Stockholm
| 2 ans |
Hanna Eiderbrant | F | 42 |
University of Stockholm
| 3 ans |
Oskar Lindholm-Wu | M | 42 |
University of Stockholm
| 3 ans |
Lova Unge | F | - |
University of Stockholm
| 5 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Suède | 41 | 75,93% |
Etats-Unis | 13 | 24,07% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Tomas Hode
- Réseau Personnel